<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19376">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854644</url>
  </required_header>
  <id_info>
    <org_study_id>P/2013/188</org_study_id>
    <nct_id>NCT02854644</nct_id>
  </id_info>
  <brief_title>Study of the Anti-tumoral Immune Response</brief_title>
  <acronym>ERISA</acronym>
  <official_title>Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the Concept in Breast Cancer and Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the frequency of the spontaneous T cells specific CD4 answers of
      tumoral antigens breast cancer and glioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous immune responses of T cells CD4 specific tumor antigens</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cells level</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with glioma and without treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all breast cancer: localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>breast cancer Hormonal estrogen Receptor 2 positive (HER2+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic breast cancer with HER2 surexpression</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional blood sample</intervention_name>
    <arm_group_label>glioma</arm_group_label>
    <arm_group_label>breast cancer</arm_group_label>
    <arm_group_label>breast cancer Hormonal estrogen Receptor 2 positive (HER2+)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status 0,1 or 2

          -  breast cancer or glioma

          -  Arm glioma: patients without anti-tumoral treatment

          -  Arm breast cancer: inclusion before treatment

          -  Arm breast cancer HER2: patients with current therapy

        Exclusion Criteria:

          -  Psychiatric disease compromising the understanding of the information or the
             realization of the study

          -  vulnerable People according to the law (minors, adults under protection, private
             persons of freedom ...)

          -  Unaffiliated People to the Social Security

          -  People being for the period of exclusion from another study

          -  Life expectancy estimated unless 3 months.

          -  For patients in Arm glioma: patients having already begun a systematic treatment.

          -  For patients with a breast cancer: patient already under current therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elsa CURTIT</last_name>
    <email>elsa.curtit@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise ROBERT</last_name>
      <phone>0381219086</phone>
      <email>e1robert@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
